Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases.
Jansen Y, Kruse V, Corthals J, Schats K, van Dam PJ, Seremet T, Heirman C, Brochez L, Kockx M, Thielemans K, Neyns B. Jansen Y, et al. Among authors: seremet t. Cancer Immunol Immunother. 2020 Dec;69(12):2589-2598. doi: 10.1007/s00262-020-02618-4. Epub 2020 Jun 26. Cancer Immunol Immunother. 2020. PMID: 32591862 Free PMC article. Clinical Trial.
Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial.
Schwarze JK, Garaud S, Jansen YJL, Awada G, Vandersleyen V, Tijtgat J, de Wind A, Kristanto P, Seremet T, Willard-Gallo K, Neyns B. Schwarze JK, et al. Among authors: seremet t. Cancers (Basel). 2022 Jan 28;14(3):682. doi: 10.3390/cancers14030682. Cancers (Basel). 2022. PMID: 35158952 Free PMC article.
Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients.
Seremet T, Koch A, Jansen Y, Schreuer M, Wilgenhof S, Del Marmol V, Liènard D, Thielemans K, Schats K, Kockx M, Van Criekinge W, Coulie PG, De Meyer T, van Baren N, Neyns B. Seremet T, et al. J Transl Med. 2016 Aug 2;14(1):232. doi: 10.1186/s12967-016-0990-x. J Transl Med. 2016. PMID: 27484791 Free PMC article.
A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab.
Awada G, Jansen Y, Schwarze JK, Tijtgat J, Hellinckx L, Gondry O, Vermeulen S, Warren S, Schats K, van Dam PJ, Kockx M, Keyaerts M, Everaert H, Seremet T, Rogiers A, Neyns B. Awada G, et al. Among authors: seremet t. Cancers (Basel). 2021 Jan 6;13(2):168. doi: 10.3390/cancers13020168. Cancers (Basel). 2021. PMID: 33418936 Free PMC article.
A Case Report of Long-Term Survival following Hepatic Arterial Infusion of L-Folinic Acid Modulated 5-Fluorouracil Combined with Intravenous Irinotecan and Cetuximab Followed by Hepatectomy in a Patient with Initially Unresectable Colorectal Liver Metastases.
Van Bael K, Jansen Y, Seremet T, Engels B, Delvaux G, Neyns B. Van Bael K, et al. Among authors: seremet t. Case Rep Oncol Med. 2015;2015:472037. doi: 10.1155/2015/472037. Epub 2015 May 6. Case Rep Oncol Med. 2015. PMID: 26064730 Free PMC article.
64 results